{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:52:18Z","timestamp":1791982338378,"version":"4.4.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.amjcard.2026.08.022","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T06:47:34Z","timestamp":1787294854000},"page":"9-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The Cancer-associated Lipid Paradox: Implications for Cardiovascular Risk and Lipid Management"],"prefix":"10.1016","volume":"278","author":[{"given":"Nicole","family":"Prescott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7373-5994","authenticated-orcid":false,"given":"Victoria J.","family":"Eichten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Ahuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney M.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7223-7360","authenticated-orcid":false,"given":"Anand","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A.","family":"Raver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1706-1961","authenticated-orcid":false,"given":"Byron","family":"Cryer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan J.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0863-7914","authenticated-orcid":false,"given":"Subhash","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2026.08.022_bib0001","article-title":"Higher risk of cardiovascular mortality than cancer mortality among long-term cancer survivors","volume":"10","author":"Wang","year":"2023","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.amjcard.2026.08.022_bib0002","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jaccao.2022.01.102","article-title":"Does cardiovascular mortality overtake cancer mortality during cancer survivorship?: an English retrospective cohort study","volume":"4","author":"Strongman","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10.1016\/j.amjcard.2026.08.022_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2024.06.006","article-title":"Cardiovascular considerations after cancer therapy: gaps in evidence and JACC: cardio oncology expert panel recommendations","volume":"7","author":"Blaes","year":"2025","journal-title":"JACC CardioOncol."},{"issue":"8","key":"10.1016\/j.amjcard.2026.08.022_bib0004","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41569-025-01126-1","article-title":"Anthracycline-induced cardiomyopathy: risk prediction, prevention and treatment","volume":"22","author":"Fabiani","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.amjcard.2026.08.022_bib0005","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.amjcard.2024.08.029","article-title":"Management of cancer therapy-related cardiac dysfunction: a case-based review","volume":"231","author":"Mallidi","year":"2024","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.1016\/j.amjcard.2026.08.022_bib0006","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/s44161-024-00563-4","article-title":"Immune checkpoint landscape of human atherosclerosis and influence of cardiometabolic factors","volume":"3","author":"Barcia Dur\u00e1n","year":"2024","journal-title":"Nat Cardiovasc Res"},{"issue":"11","key":"10.1016\/j.amjcard.2026.08.022_bib0007","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjcard.2026.08.022_bib0008","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-00666-z","article-title":"Lipid profiles and outcomes of patients with prior cancer and subsequent myocardial infarction or stroke","volume":"11","author":"Koo","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.amjcard.2026.08.022_bib0009","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1161\/CIRCRESAHA.118.313591","article-title":"Immunity and inflammation in atherosclerosis","volume":"124","author":"Wolf","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.amjcard.2026.08.022_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119219","article-title":"Accelerated atherosclerosis associated with immune checkpoint inhibitors: a systematic review and meta-analysis of pre-clinical studies","volume":"405","author":"Strijdhorst","year":"2025","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.amjcard.2026.08.022_bib0011","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s12672-025-02430-5","article-title":"Research progress on cholesterol metabolism and tumor therapy","volume":"16","author":"Chu","year":"2025","journal-title":"Discov Oncol"},{"issue":"6","key":"10.1016\/j.amjcard.2026.08.022_bib0012","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s11239-024-02993-0","article-title":"Cancer progression and tumor hypercoagulability: a platelet perspective","volume":"57","author":"Zhang","year":"2024","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.amjcard.2026.08.022_bib0013","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.amjcard.2025.08.013","article-title":"Systemic review of inflammatory pathways and immune modulation in atherosclerotic cardiovascular disease","volume":"258","author":"Wang","year":"2026","journal-title":"Am J Cardiol"},{"issue":"10","key":"10.1016\/j.amjcard.2026.08.022_bib0014","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3390\/cancers10100380","article-title":"Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment","volume":"10","author":"Abdol Razak","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.amjcard.2026.08.022_bib0015","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jaccao.2020.08.007","article-title":"Immune checkpoint inhibitor therapy aggravates T cell-driven plaque inflammation in atherosclerosis","volume":"2","author":"Poels","year":"2020","journal-title":"JACC CardioOncol"},{"issue":"6","key":"10.1016\/j.amjcard.2026.08.022_bib0016","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1152\/japplphysiol.00471.2022","article-title":"A bench to bedside perspective on anthracycline chemotherapy-mediated cardiovascular dysfunction: challenges and opportunities. A symposium review","volume":"133","author":"Clayton","year":"2022","journal-title":"J Appl Physiol (1985)"},{"issue":"4","key":"10.1016\/j.amjcard.2026.08.022_bib0017","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11523-011-0203-8","article-title":"Heart to heart with trastuzumab: a review on cardiac toxicity","volume":"6","author":"Di Cosimo","year":"2011","journal-title":"Target Oncol"},{"issue":"11","key":"10.1016\/j.amjcard.2026.08.022_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26115401","article-title":"A comprehensive review of radiotherapy-induced coronary artery disease-epidemiology, biological mechanisms, and preventive strategies","volume":"26","author":"Daher","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.amjcard.2026.08.022_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13081895","article-title":"Lipid metabolism reprogramming in cancer: insights into tumor cells and immune cells within the tumor microenvironment","volume":"13","author":"Liu","year":"2025","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.amjcard.2026.08.022_bib0020","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41598-023-50931-6","article-title":"Association between total cholesterol levels and all-cause mortality among newly diagnosed patients with cancer","volume":"14","author":"Kim","year":"2024","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.amjcard.2026.08.022_bib0021","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/ajcn\/71.2.569","article-title":"Association of low plasma cholesterol with mortality for cancer at various sites in men: 17-y follow-up of the prospective Basel study","volume":"71","author":"Eichholzer","year":"2000","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.amjcard.2026.08.022_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1254339","article-title":"Association between lipid variability and the risk of mortality in cancer patients not receiving lipid-lowering agents","volume":"13","author":"Kim","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.amjcard.2026.08.022_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2026.120683","article-title":"Association of cancer on coronary atherosclerotic burden and plaque rupture: insights from the BRAVADO study","volume":"415","author":"Seleme","year":"2026","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.amjcard.2026.08.022_bib0024","first-page":"689","article-title":"Lipid metabolism and breast cancer: a narrative review of the prognostic implications and chemotherapy-induced dyslipidemia","volume":"15","author":"Faur","year":"2025","journal-title":"Life (Basel)"},{"issue":"1","key":"10.1016\/j.amjcard.2026.08.022_bib0025","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12944-022-01694-y","article-title":"Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage?","volume":"21","author":"Abrahams","year":"2022","journal-title":"Lipids Health Dis"},{"issue":"3","key":"10.1016\/j.amjcard.2026.08.022_bib0026","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1159\/000518684","article-title":"Severe hypertriglyceridemia induced by Docetaxel: a novel case report","volume":"14","author":"Saito","year":"2021","journal-title":"Case Rep Oncol"},{"issue":"2","key":"10.1016\/j.amjcard.2026.08.022_bib0027","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pcad.2010.06.007","article-title":"Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?","volume":"53","author":"Sawyer","year":"2010","journal-title":"Prog Cardiovasc Dis"},{"issue":"6","key":"10.1016\/j.amjcard.2026.08.022_bib0028","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","article-title":"Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology","volume":"121","author":"Levine","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2026.08.022_bib0029","first-page":"61","article-title":"Treating alpelisib-induced hyperinsulinemia in patients with advanced breast cancer: a real-life experience","volume":"17","author":"Percik","year":"2023","journal-title":"Biologics"},{"issue":"2","key":"10.1016\/j.amjcard.2026.08.022_bib0030","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3892\/mco.2016.1107","article-title":"Paclitaxel and platinum-based chemotherapy results in transient dyslipidemia in cancer patients","volume":"6","author":"Wang","year":"2017","journal-title":"Mol Clin Oncol"},{"issue":"12","key":"10.1016\/j.amjcard.2026.08.022_bib0031","first-page":"4453","article-title":"Effects of chemotherapy-induced castration on serum lipids and apoproteins in premenopausal women with node-positive breast cancer","volume":"81","author":"Saarto","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"13","key":"10.1016\/j.amjcard.2026.08.022_bib0032","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241311153","article-title":"Low-density lipoprotein receptor is a key driver of aggressiveness in thyroid tumor cells","volume":"24","author":"Revilla","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.amjcard.2026.08.022_bib0033","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.tips.2024.04.007","article-title":"Emerging targets in lipid metabolism for cancer therapy","volume":"45","author":"Terry","year":"2024","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"10.1016\/j.amjcard.2026.08.022_bib0034","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3892\/mmr.2012.758","article-title":"Role of liver X receptors in cholesterol efflux and inflammatory signaling (review)","volume":"5","author":"Zhu","year":"2012","journal-title":"Mol Med Rep"},{"issue":"5","key":"10.1016\/j.amjcard.2026.08.022_bib0035","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/ijc.30526","article-title":"Effects of statins on cancer mortality and progression: a systematic review and meta-analysis of 95 cohorts including 1,111,407 individuals","volume":"140","author":"Mei","year":"2017","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.amjcard.2026.08.022_bib0036","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12944-023-01955-4","article-title":"The association of statin therapy and cancer: a meta-analysis","volume":"22","author":"Chen","year":"2023","journal-title":"Lipids Health Dis"},{"issue":"20","key":"10.1016\/j.amjcard.2026.08.022_bib0037","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.036411","article-title":"Statin therapy reduces radiation-induced cardiotoxicity in patients with breast cancer receiving adjuvant radiotherapy","volume":"13","author":"Huang","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.amjcard.2026.08.022_bib0038","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s11912-022-01212-4","article-title":"Statins for cardiac and vascular protection during and after cancer therapy","volume":"24","author":"Heiston","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.amjcard.2026.08.022_bib0039","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.amjcard.2021.07.001","article-title":"Meta-analysis evaluating the use of statins to attenuate cardiotoxicity in cancer patients receiving anthracyclines and trastuzumab-based chemotherapy","volume":"156","author":"Shahid","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2026.08.022_bib0040","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.amjcard.2023.08.123","article-title":"Statins for primary prevention of anthracycline chemotherapy-related cardiac dysfunction: a systematic review and meta-analysis of randomized controlled trials","volume":"206","author":"Agarwal","year":"2023","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.amjcard.2026.08.022_bib0041","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jamainternmed.2020.6084","article-title":"Evaluation of time to benefit of statins for the primary prevention of cardiovascular events in adults aged 50 to 75 years: a meta-analysis","volume":"181","author":"Yourman","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"10","key":"10.1016\/j.amjcard.2026.08.022_bib0042","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.38737","article-title":"Postdiagnosis statin use and breast cancer mortality","volume":"8","author":"Harborg","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.amjcard.2026.08.022_bib0043","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/joim.12806","article-title":"Statins: a role in breast cancer therapy?","volume":"284","author":"Borgquist","year":"2018","journal-title":"J Intern Med"},{"issue":"4","key":"10.1016\/j.amjcard.2026.08.022_bib0044","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41416-025-03070-w","article-title":"Statin use and breast cancer-specific mortality and recurrence: a systematic review and meta-analysis including the role of immortal time bias and tumour characteristics","volume":"133","author":"Scott","year":"2025","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.amjcard.2026.08.022_bib0045","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jamaoncol.2017.2752","article-title":"Examining bias in studies of statin treatment and survival in patients with cancer [Erratum in: JAMA Oncol. 2018 Jan 1;4(1):133]","volume":"4","author":"Emilsson","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.amjcard.2026.08.022_bib0046","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejim.2024.04.007","article-title":"Cardio-protective effects of statins in patients undergoing anthracycline-based chemotherapy: an updated meta-analysis of randomized controlled trials","volume":"126","author":"Felix","year":"2024","journal-title":"Eur J Intern Med"},{"issue":"4","key":"10.1016\/j.amjcard.2026.08.022_bib0047","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s11764-020-00865-z","article-title":"Rates of underuse of statins among cancer survivors versus controls: NHANES 2011-2016","volume":"14","author":"Jeong","year":"2020","journal-title":"J Cancer Surviv"},{"issue":"1","key":"10.1016\/j.amjcard.2026.08.022_bib0048","first-page":"28","article-title":"Statin initiation among cancer survivors with asymptomatic coronary atherosclerosis","volume":"12","author":"Soh","year":"2026","journal-title":"Cardiooncology"},{"key":"10.1016\/j.amjcard.2026.08.022_bib0049","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2147\/CLEP.S509873","article-title":"Statin therapy in early breast cancer: the MASTER trial; a randomized phase III, placebo-controlled comparison of standard (neo)adjuvant therapy plus atorvastatin versus standard (neo)adjuvant therapy plus placebo","volume":"17","author":"Borgquist","year":"2025","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.amjcard.2026.08.022_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175721","article-title":"The evolving landscape of PCSK9 inhibition in cancer","volume":"949","author":"Oza","year":"2023","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"10.1016\/j.amjcard.2026.08.022_bib0051","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1161\/CIRCRESAHA.121.320056","article-title":"Proprotein convertase Subtilisin\/Kexin 9 (PCSK9) promotes macrophage activation via LDL receptor-independent mechanisms","volume":"131","author":"Katsuki","year":"2022","journal-title":"Circ Res"},{"issue":"5","key":"10.1016\/j.amjcard.2026.08.022_bib0052","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051397","article-title":"PCSK9 Inhibitors in cancer patients treated with immune-checkpoint Inhibitors to reduce cardiovascular events: new frontiers in cardioncology","volume":"15","author":"Quagliariello","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"24","key":"10.1016\/j.amjcard.2026.08.022_bib0053","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jacc.2023.10.007","article-title":"Safety and tolerability of inclisiran for treatment of hypercholesterolemia in 7 clinical trials","volume":"82","author":"Wright","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2026.08.022_bib0054","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.amjcard.2025.02.034","article-title":"Lipoprotein(a): from biomarker to therapy: a review for the clinician","volume":"245","author":"Jha","year":"2025","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.amjcard.2026.08.022_bib0055","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.amjcard.2026.08.022_bib0056","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1161\/01.ATV.17.5.905","article-title":"In vivo transfer of lipoprotein(a) into human atherosclerotic carotid arterial intima","volume":"17","author":"Nielsen","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2026.08.022_bib0057","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.semcancer.2025.09.008","article-title":"The complex interplay of lipoprotein(a) and cancer in the era of emerging therapeutics","volume":"116","author":"Bianconi","year":"2025","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"10.1016\/j.amjcard.2026.08.022_bib0058","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ctrv.2007.02.006","article-title":"Lipoprotein[a] and cancer: anti-neoplastic effect besides its cardiovascular potency","volume":"33","author":"Lippi","year":"2007","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.amjcard.2026.08.022_bib0059","doi-asserted-by":"crossref","DOI":"10.3390\/jcm15062179","article-title":"Existing and potential therapeutic strategies for lowering lipoprotein(a) levels: an update","volume":"15","author":"Doma\u0144ski","year":"2026","journal-title":"J Clin Med"},{"issue":"17","key":"10.1016\/j.amjcard.2026.08.022_bib0060","first-page":"e1154","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"153","author":"Blumenthal","year":"2026","journal-title":"Circulation"},{"issue":"41","key":"10.1016\/j.amjcard.2026.08.022_bib0061","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2026.08.022_bib0062","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.amjcard.2026.02.059","article-title":"2025 ESC\/EAS Dyslipidemia guidelines focused update: Intensifying prevention, Risk stratification, and therapy","volume":"267","author":"Pradhan","year":"2026","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.amjcard.2026.08.022_bib0063","first-page":"19","article-title":"Association of PCSK9 inhibitors versus statins with cancer incidence: a target trial emulation","volume":"12","author":"Huang","year":"2026","journal-title":"Cardiooncology"},{"key":"10.1016\/j.amjcard.2026.08.022_bib0064","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.amjcard.2023.08.123","article-title":"Statins for primary prevention of anthracycline chemotherapy-related cardiac dysfunction: a systematic review and meta-analysis of randomized controlled trials","volume":"206","author":"Agarwal","year":"2023","journal-title":"Am J Cardiol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000291492600531X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000291492600531X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:32:43Z","timestamp":1791981163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000291492600531X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":64,"alternative-id":["S000291492600531X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.08.022","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Cancer-associated Lipid Paradox: Implications for Cardiovascular Risk and Lipid Management","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.08.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}